Literature DB >> 15753384

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

Ming Tan1, Ping Li, Kristine S Klos, Jing Lu, Keng-Hsueh Lan, Yoichi Nagata, Dexing Fang, Tong Jing, Dihua Yu.   

Abstract

Activation of Src kinase plays important roles in the development of many neoplasias. Most of the previous Src studies focused on the deregulation of Src kinase activity. The deregulated Src protein synthesis and stability in mediating malignant phenotypes of cancer cells, however, have been neglected. While investigating the signal transduction pathways contributing to ErbB2-mediated metastasis, we found that ErbB2-activated breast cancer cells that had higher metastatic potentials also had increased Src activity compared with ErbB2 low-expressing cells. The increased Src activity in ErbB2-activated cells paralleled higher Src protein levels, whereas Src RNA levels were not significantly altered. Our studies revealed two novel mechanisms that are involved in Src protein up-regulation and activation by ErbB2: (a) ErbB2 increased Src translation through activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway and (b) ErbB2 increased Src stability most likely through the inhibition of the calpain protease. Furthermore, inhibition of Src activity by a Src-specific inhibitor, PP2, or a Src dominant-negative mutant dramatically reduced ErbB2-mediated cancer cell invasion in vitro and metastasis in an experimental metastasis animal model. Together, activation of ErbB2 and downstream signaling pathways can lead to increased Src protein synthesis and decreased Src protein degradation resulting in Src up-regulation and activation, which play critical roles in ErbB2-mediated breast cancer invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15753384     DOI: 10.1158/0008-5472.CAN-04-2353

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

2.  ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Authors:  Valerie S Hawthorne; Wen-Chien Huang; Christopher L Neal; Ling-Min Tseng; Mien-Chie Hung; Dihua Yu
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

3.  HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42.

Authors:  Emhonta Johnson; Darcie D Seachrist; Carlos M DeLeon-Rodriguez; Kristen L Lozada; John Miedler; Fadi W Abdul-Karim; Ruth A Keri
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

4.  ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Authors:  Dannah R Miller; Matthew A Ingersoll; Ming-Fong Lin
Journal:  Endocr Relat Cancer       Date:  2019-04-01       Impact factor: 5.678

Review 5.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

6.  PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.

Authors:  Hamid H Gari; Gregory D DeGala; Rahul Ray; M Scott Lucia; James R Lambert
Journal:  Cancer Lett       Date:  2016-07-21       Impact factor: 8.679

7.  ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

Authors:  D M Kambach; V L Sodi; P I Lelkes; J Azizkhan-Clifford; M J Reginato
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

8.  Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Authors:  B L Allen-Petersen; C J Carter; A M Ohm; M E Reyland
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

9.  Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.

Authors:  Itai Pashtan; Shinji Tsutsumi; Suiquan Wang; Wanping Xu; Len Neckers
Journal:  Cell Cycle       Date:  2008-09-30       Impact factor: 4.534

10.  Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis.

Authors:  Sharon J Sequeira; Huei Chi Wen; Alvaro Avivar-Valderas; Eduardo F Farias; Julio A Aguirre-Ghiso
Journal:  BMC Cell Biol       Date:  2009-09-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.